Amundi’s TG Therapeutics TGTX Stock Holding History

Amundi’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.27M	Buy	23,037 +9,192	+66%	+$376K	﹤0.01%	1294
2026 Q1	$460K	Buy	+13,845	New	+$413K	﹤0.01%	1575
2023 Q1	–	Sell	-11,009	Closed	-$144K	–	2122
2022 Q4	$144K	Sell	11,009 -1,585	-13%	-$11.5K	﹤0.01%	1559
2022 Q3	$79K	Buy	+12,594	New	+$82.6K	﹤0.01%	1595
2022 Q2	–	Sell	-5,726	Closed	-$56K	–	1715
2022 Q1	$56K	Hold	5,726	–	–	﹤0.01%	1527
2021 Q4	$88K	Hold	5,726	–	–	﹤0.01%	1583
2021 Q3	$191K	Hold	5,726	–	–	﹤0.01%	1445
2021 Q2	$222K	Buy	+5,726	New	+$225K	﹤0.01%	1362

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Amundi's TGTX Position: Q2 2026 in Review

Amundi increased its TG Therapeutics (TGTX) stake by 66% in Q2 2026, buying an estimated $376K and bringing the position to 23,037 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #1294.

Amundi first reported a position in TGTX in Q2 2021 and has held it in 8 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Amundi held 23,037 shares of TG Therapeutics worth $1.27M as of Q2 2026.
Amundi bought 9,192 TG Therapeutics shares in Q2 2026, an estimated $376K.
TG Therapeutics made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1294 holding.
Amundi first reported a position in TG Therapeutics in Q2 2021 and has held it in 8 quarters since.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.